Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds JP Morgan Downgrades Plexus to Underweight

JP Morgan Downgrades Plexus to Underweight

JP Morgan analyst Paul Coster downgrades Plexus (NASDAQ:PLXS) from Neutral to Underweight.

byBenzinga Newsdesk

August 12, 2022

1 minute read

JP Morgan analyst Paul Coster downgrades Plexus (NASDAQ:PLXS) from Neutral to Underweight.

Belden Lowers Q3 Revenue Expectations Because ‘Softer Demand Will Continue,’ CEO Says

By Lekha Gupta

October 13, 9:27 AM

Belden Inc (NYSE: BDC) disclosed third-quarter (Q3) FY23 preliminary results,

BDC

BurgerFi International Inc. Announces Chris Jones As CFO On July 10, 2023

By Benzinga Newsdesk

June 13, 9:08 AM

Continues to build leadership team, focuses on next stage of growthBurgerFi International Inc. (NASDAQ:BFI, BFIIW)))) ("BurgerFi" or the "Company"), owner of leading fast-casual brand BurgerFi and the casual dining pizza

BFI

HC Wainwright & Co. Reiterates Buy on BriaCell Therapeutics, Maintains $25 Price Target

By Benzinga Newsdesk

February 24, 7:29 AM

HC Wainwright & Co. analyst Emily Bodnar reiterates BriaCell Therapeutics (NASDAQ:BCTX) with a Buy and maintains $25 price target.

BCTX

Wedbush Assumes New York Community at Neutral, Announces Price Target of $10

By Benzinga Newsdesk

September 28, 9:29 AM

Wedbush analyst David Chiaverini assumes New York Community (NYSE:NYCB) with a Neutral rating and announces Price Target of $10.

NYCB

JP Morgan Downgrades Plexus to Underweight

Related Posts

Belden Lowers Q3 Revenue Expectations Because ‘Softer Demand Will Continue,’ CEO Says

BurgerFi International Inc. Announces Chris Jones As CFO On July 10, 2023

HC Wainwright & Co. Reiterates Buy on BriaCell Therapeutics, Maintains $25 Price Target

Wedbush Assumes New York Community at Neutral, Announces Price Target of $10